ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC By Ogkologos - May 21, 2026 133 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TOMBOLA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR GreaterGood’s Inaugural Breast Cancer Research Professor Is Changing the Face of... October 1, 2020 Foodie Friday: Couscous Salad August 13, 2021 FDA Approves First Comprehensive Pan-Tumour Liquid Biopsy Test for Patients with... September 3, 2020 Toxin-Based Drug Moxetumomab Pasudotox May Be New Option for Rare Leukemia June 5, 2018 Load more HOT NEWS Pembrolizumab Approved for Some Patients with Advanced Esophageal Cancer Efficacy and Safety of Adjuvant Nivolumab for High-Risk Muscle-Invasive Urothelial Carcinoma... EMA Recommends Extension of Indications for Pembrolizumab to MSI-H or dMMR... Cancer in My Community: Reducing Tobacco Use in Tunisia
